Key takeaways for Pennsylvania
- • No GLP-1 is FDA-approved for pre/post-bariatric use specifically.
- • Pre-op: liver shrinkage and risk optimization; post-op: regain management.
- • Observational data show 8-15% additional weight loss post-op on GLP-1.
- • Pennsylvania Medical Assistance (HealthChoices) coverage rules apply for Bariatric Pre- and Post-Op Support patients in Pennsylvania — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Bariatric Pre- and Post-Op Support
No GLP-1 is FDA-approved specifically for bariatric pre/post-op support. Off-label preoperative use can reduce liver volume and improve surgical access; off-label postoperative use addresses the roughly 25-30% of bariatric patients who experience clinically significant weight regain. Evidence grade: C (observational data growing; few RCTs). The ASMBS 2022 statement and emerging 2024-2025 consensus recognize this as an evolving practice. Pancreatitis and gastroparesis risks may merit extra caution in altered post-op anatomy.
Pennsylvania-specific context
Pennsylvania has telehealth access concentrated in Philadelphia, Pittsburgh, Allentown metros, with additional reach to Erie and Reading. UPMC, Penn Medicine, Children's Hospital of Philadelphia is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.health.pa.gov.
Pennsylvaniatelehealth & pricing rules
- • Pennsylvania permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Pennsylvania allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Pennsylvania: (compounded options often lower, brand higher).